40 and older, any sex, with Pseudophakia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Binocular DCNVA (Distance Corrected Near Visual Acuity) at 40cmPrimary· 3 months post operatively
Binocular DCNVA Visual acuity testing will be measured in LogMar and all study technicians and evaluators will be masked. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
Group
Value
95% CI
Alcon PanOptix
0.03
± 0.08
Johnson & Johnson Synergy
0.01
± 0.07
Binocular Corrected Distance Visual Acuity (CDVA) Measured at 4m.Secondary· 3 months post operatively
Binocular CDVA measured at 4m. Visual acuity testing will be measured in LogMar and all study technicians and evaluators will be masked. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
Group
Value
95% CI
Alcon PanOptix
-0.06
± 0.06
Johnson & Johnson Synergy
-0.07
± 0.07
Binocular Distance Corrected Intermediate Visual Acuity (DCIVA) Measured at 60cm.Secondary· 3 months post operatively
Binocular DCIVA measured at 60cm. Visual acuity testing will be measured in LogMar and all study technicians and evaluators will be masked. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
Group
Value
95% CI
Alcon PanOptix
0.00
± 0.08
Johnson & Johnson Synergy
0.00
± 0.07
Binocular Uncorrected Distance Visual Acuity (UDVA) Measured at 4m.Secondary· 3 months post operatively
Binocular UDVA measured at 4m. Visual acuity testing will be measured in LogMar and all study technicians and evaluators will be masked. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
Group
Value
95% CI
Alcon PanOptix
-0.01
± 0.08
Johnson & Johnson Synergy
0.00
± 0.08
Binocular Uncorrected Intermediate Visual Acuity (UIVA) Measured at 60cm.Secondary· 3 months post operatively
Binocular UIVA measured at 60cm. Visual acuity testing will be measured in LogMar and all study technicians and evaluators will be masked. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
Group
Value
95% CI
Alcon PanOptix
0.00
± 0.08
Johnson & Johnson Synergy
0.00
± 0.08
Binocular Uncorrected Near Visual Acuity (UNVA) Measured at 40cm.Secondary· 3 months post operatively
Binocular UNVA measured at 40cm. Visual acuity testing will be measured in LogMar and all study technicians and evaluators will be masked. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
Group
Value
95% CI
Alcon PanOptix
0.03
± 0.08
Johnson & Johnson Synergy
0.03
± 0.08
Binocular Target Corrected Defocus CurveSecondary· 3 months post operatively
Binocular target corrected defocus curve. Visual acuity testing will be measured in LogMar and all study technicians and evaluators will be masked. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
-3.00 D
Group
Value
95% CI
Alcon PanOptix
0.12
± 0.09
Johnson & Johnson Synergy
0.09
± 0.09
-2.50 D
Group
Value
95% CI
Alcon PanOptix
0.03
± 0.08
Johnson & Johnson Synergy
0.03
± 0.09
-2.00 D
Group
Value
95% CI
Alcon PanOptix
-0.01
± 0.08
Johnson & Johnson Synergy
0.01
± 0.09
-1.50 D
Group
Value
95% CI
Alcon PanOptix
0.02
± 0.09
Johnson & Johnson Synergy
0.02
± 0.09
-1.00 D
Group
Value
95% CI
Alcon PanOptix
0.10
± 0.09
Johnson & Johnson Synergy
0.06
± 0.09
-0.50 D
Group
Value
95% CI
Alcon PanOptix
0.06
± 0.07
Johnson & Johnson Synergy
0.03
± 0.07
-0.25 D
Group
Value
95% CI
Alcon PanOptix
-0.02
± 0.07
Johnson & Johnson Synergy
-0.04
± 0.06
0.00 D
Group
Value
95% CI
Alcon PanOptix
-0.07
± 0.07
Johnson & Johnson Synergy
-0.06
± 0.06
Patient Reported Satisfaction by IOLSAT Questionnaire.Secondary· 3 months post operatively
Patient reported satisfaction by IOLSAT questionnaire will be assessed. Variables measured on a categorical scale will be summarized to provide the number and percentage of subjects who provided each score. The percentage of patients "Satisfied" or "Very Satisfied" will be added for a total satisfaction percentage.
Group
Value
95% CI
Alcon PanOptix
89
Johnson & Johnson Synergy
94
Patient Reported Dysphotopsias Questionnaire (QUVID).Secondary· 3 months post operatively
Patient reported disphotopsias by QUVID questionnaire will be assessed. Variables measured on a categorical scale will be summarized to provide the number and percentage of subjects who provided each score. The percentage of subjects that answered "Never" for frequency are provided.
Starbursts
Group
Value
95% CI
Alcon PanOptix
65
Johnson & Johnson Synergy
49
Halos
Group
Value
95% CI
Alcon PanOptix
38
Johnson & Johnson Synergy
38
Glare
Group
Value
95% CI
Alcon PanOptix
48
Johnson & Johnson Synergy
55
Haze
Group
Value
95% CI
Alcon PanOptix
84
Johnson & Johnson Synergy
86
Blurred Vision
Group
Value
95% CI
Alcon PanOptix
87
Johnson & Johnson Synergy
75
Double Vision
Group
Value
95% CI
Alcon PanOptix
97
Johnson & Johnson Synergy
100
Dark Area
Group
Value
95% CI
Alcon PanOptix
98
Johnson & Johnson Synergy
96
Post Operative Refraction, Manifest Refraction Spherical Equivalent (MRSE).Secondary· 3 months post operatively
Post operative refraction. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
Group
Value
95% CI
Alcon PanOptix
0.24
± 0.26
Johnson & Johnson Synergy
0.23
± 0.26
Spectacle Independence Utilizing the IOLSAT.Secondary· 3 months post operatively
Spectacle independence utilizing the IOLSAT will be assessed. Variables measured on a categorical scale will be summarized to provide the number and percentage of subjects who provided each score. Spectacle independence was defined as answering "Never" or "Rarely" on the IOLSAT, the data presented is the percentage of subjects answering "Never" or "Rarely".
Overall
Group
Value
95% CI
Alcon PanOptix
92
Johnson & Johnson Synergy
97
Distance
Group
Value
95% CI
Alcon PanOptix
99
Johnson & Johnson Synergy
100
Intermediate
Group
Value
95% CI
Alcon PanOptix
99
Johnson & Johnson Synergy
100
Near
Group
Value
95% CI
Alcon PanOptix
93
Johnson & Johnson Synergy
96
Binocular Distacne Corrected Near Visual Acuity (DCNVA) at 33cm.Secondary· 3 months post operatively
Binocular DCNVA at 33cm. Visual acuity testing will be measured in LogMar and all study technicians and evaluators will be masked. A summary of the data will be prepared for all subjects and categorized by the lens implanted. Variables measured on a continuous scale will be summarized to include sample size as well as the mean, standard deviation, median, minimum and maximum.
Group
Value
95% CI
Alcon PanOptix
0.09
± 0.09
Johnson & Johnson Synergy
0.04
± 0.08
Sponsor's own description
Background:
* The Tecnis Synergy intraocular lens (IOL) has a claim to allow patients to experience continuous high-contrast vision from far through near even in low-light conditions.
* A J\&J-sponsored post marketing study done outside of the US claim superiority of range of vision for the Tecnis Synergy IOL over the PanOptix IOL.
Hypothesis:
* Patients with bilateral Panoptix IOLs have non-inferior distance, intermediate, and near visual acuity compared to patients with bilateral Synergy IOLs in both photopic and mesopic conditions with less glare, haloes, and/or starbursts.
Unmet Medical Need:
* There is a need to look at patient visual outcomes and the visual disturbance profile comparing trifocal technology with combined EDOF/Bifocal technology in the United States.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06963138 — Comparative Study and Validation of New Methodologies for Measuring Addition
· NA
· completed
NCT06064916 — Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients
· completed
NCT05611073 — Maximizing Visual Outcomes With Eyhance IOLs
· completed
NCT05226884 — Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs
· completed
NCT04420962 — Automated Quantitative Ulcer Analysis Study
· completed
Other recruiting trials for Pseudophakia
Currently open trials in the same condition.
NCT04692012 — Treatment of Residual Hypermetropic Refraction on Pseudophakic Patients Using Allogenic Fresh Myopic Lenticule
· NA
· active not recruiting
Other Berkeley Eye Center trials
Trials by the same sponsor.
NCT07475832 — Comparison of Two Biometers in Dense Cataracts
· completed
NCT06064916 — Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients
· completed
NCT06045325 — Assessment of Measurement Variability Across Automated Biometry Devices
· completed
NCT05611073 — Maximizing Visual Outcomes With Eyhance IOLs
· completed
NCT05226884 — Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Berkeley Eye Center
Last refreshed: 23 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06041139.